CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Financial Statements and Exhibits

CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

99.1 Press release issued by the Company on February12, 2018.
Story continues below


EX-99.1 2 d519606dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse®     •   Positive meeting with the FDA about the resubmission of an NDA for Firdapse     •   Resubmission of NDA for Firdapse on schedule for end of the first quarter CORAL GABLES,…
To view the full exhibit click here


Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy.

An ad to help with our costs